mRNA therapy for phenylketonuria
AssigneeTranslate Bio, Inc.
InventorsFrank DeRosa, Michael Heartlein, Anusha Dias
Life of this patent
Estimating the term…
Abstract
The present invention provides, among other things, methods of treating phenylketonuria (PKU), including administering to a subject in need of treatment a composition comprising an mRNA encoding phenylalanine hydroxylase (PAH) at an effective dose and an administration interval such that at least one symptom or feature of PKU is reduced in intensity, severity, or frequency or has delayed in onset. In some embodiments, the mRNA is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.
Claims10
A method of treating phenylketonuria (PKU), comprising systemically administering to a subject in need of treatment a composition comprising an mRNA encoding phenylalanine hydroxylase (PAH), wherein the mRNA comprises a coding nucleotide sequence at least 95% identical to the mRNA sequence of SEQ ID NO:
- 3, a 5′ untranslated region (UTR) sequence of SEQ ID NO:4, and a 3′ UTR sequence of SEQ ID NO:5 or SEQ ID NO:6, wherein the mRNA is encapsulated within a liposome with a size of less than 100 nm, wherein the liposome comprises one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids, and wherein administration of the composition at an effective dose and at an administration interval results in increased PAH protein level in the liver and in reduced phenylalanine level in the serum as compared to the baseline of PAH and phenylalanine levels before the treatment.
Dependencies are inferred from the claim text.